{"id":134,"date":"2026-08-26T17:25:00","date_gmt":"2026-08-26T17:25:00","guid":{"rendered":"https:\/\/kfree.app\/blog\/?p=134"},"modified":"2026-08-26T17:25:02","modified_gmt":"2026-08-26T17:25:02","slug":"dea-kratom-schedule-i-7-oh","status":"publish","type":"post","link":"https:\/\/kfree.app\/blog\/dea-kratom-schedule-i-7-oh\/","title":{"rendered":"DEA Schedules Three Kratom-Related Opioids: What 7-OH Users Should Know"},"content":{"rendered":"\n

<\/p>\n\n\n\n

If you use 7-OH and you’ve been following the news lately, you may be wondering whether the federal government has finally banned it.<\/p>\n\n\n\n

As of August 26, 2026, the answer is no\u2014not yet.<\/strong><\/p>\n\n\n\n

The DEA has now placed three potent kratom-related compounds into Schedule I: mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16.<\/strong><\/p>\n\n\n\n

But the separate federal action targeting concentrated 7-hydroxymitragynine, or 7-OH, is still in progress<\/strong>. In fact, federal officials just extended the public-comment period surrounding the proposed 7-OH threshold through September 10.<\/p>\n\n\n\n

That distinction matters because several federal actions are happening around kratom-derived products at the same time, and it’s becoming very easy to read a headline and walk away thinking:<\/p>\n\n\n\n

“The DEA just banned kratom.”<\/strong><\/p>\n\n\n\n

That’s not what happened.<\/p>\n\n\n\n

And if you’re currently using 7-OH, I think it’s worth understanding what did<\/em> happen\u2014not just because of the legal details, but because the market around these products may be about to change considerably.<\/p>\n\n\n\n

\n\n\n\n

What Did the DEA Just Put Into Schedule I?<\/h2>\n\n\n\n

On August 25, the Department of Justice announced the emergency scheduling of three compounds:<\/p>\n\n\n\n

    \n
  • Mitragynine pseudoindoxyl (MGPI)<\/strong><\/li>\n\n\n\n
  • MGM-15<\/strong><\/li>\n\n\n\n
  • MGM-16<\/strong><\/li>\n<\/ul>\n\n\n\n

    The temporary scheduling order takes effect upon publication in the Federal Register on August 26.<\/p>\n\n\n\n

    These aren’t simply other names for ordinary kratom powder.<\/p>\n\n\n\n

    They’re potent opioid compounds chemically related to mitragynine or 7-OH. According to the Justice Department, MGPI and MGM-15 have already been manufactured and marketed in consumer products for their opioid effects. MGM-16 has not been confirmed in the consumer market, but federal officials are acting before it potentially emerges as an alternative to related compounds.<\/p>\n\n\n\n

    This is an important change from where things stood earlier this summer.<\/p>\n\n\n\n

    In July, DEA announced that it intended<\/strong> to temporarily schedule these compounds.<\/p>\n\n\n\n

    Now it’s actually happening.<\/p>\n\n\n\n

    Once the order takes effect, MGPI, MGM-15, and MGM-16 become subject to the federal controls that apply to Schedule I controlled substances.<\/p>\n\n\n\n

    But there’s one thing I want to make especially clear:<\/p>\n\n\n\n

    This is not the same federal action as the proposed scheduling of concentrated 7-OH.<\/strong><\/p>\n\n\n\n

    \n\n\n\n
    \"\"<\/figure>\n\n\n\n
    \n\n\n\n

    So, Is 7-OH Banned Federally?<\/h2>\n\n\n\n

    Not under the separate 7-OH scheduling action\u2014not yet.<\/strong><\/p>\n\n\n\n

    This is where things get confusing.<\/p>\n\n\n\n

    Back in July, DEA announced its intent to temporarily place 7-OH above a specified threshold<\/strong> into Schedule I.<\/p>\n\n\n\n

    The key phrase is above a specified threshold<\/em>.<\/p>\n\n\n\n

    DEA didn’t propose simply putting every detectable amount of 7-OH into Schedule I. Its proposed framework distinguishes elevated or concentrated 7-OH products from the trace amounts that can occur in botanical kratom.<\/p>\n\n\n\n

    And on August 26, there was another important development.<\/p>\n\n\n\n

    The Office of the Assistant Secretary for Health extended the public-comment period concerning that proposed threshold until September 10, 2026<\/strong>.<\/p>\n\n\n\n

    The notice is fairly narrow. It’s asking for input concerning the threshold used for temporary scheduling. It isn’t reopening the entire question of kratom, deciding whether kratom products are generally useful or safe, or making a permanent scheduling decision.<\/p>\n\n\n\n

    So as I write this, the easiest way to understand the situation is:<\/p>\n\n\n\n

    MGPI, MGM-15, and MGM-16:<\/strong> being placed into Schedule I now.<\/p>\n\n\n\n

    Concentrated 7-OH above DEA’s proposed threshold:<\/strong> still going through a separate temporary-scheduling process.<\/p>\n\n\n\n

    Traditional botanical kratom below the proposed threshold:<\/strong> not included in that proposed 7-OH scheduling action.<\/p>\n\n\n\n

    Those are three different things.<\/p>\n\n\n\n

    And right now, they’re getting blurred together constantly.<\/p>\n\n\n